Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

OTC EPINEPHRINE RELABELING TO ADDRESS INAPPROPRIATE USE

This article was originally published in The Tan Sheet

Executive Summary

OTC EPINEPHRINE RELABELING TO ADDRESS INAPPROPRIATE USE was suggested by Nonprescription Drugs Advisory Committee Chair Randy Juhl, PhD, University of Pittsburgh, as one way of dealing with concerns raised during a Nov. 14 joint meeting of NDAC and the Pulmonary-Allergy Drugs Advisory Committee, Speaking in favor of maintaining inhaled epinephrine's OTC availability, Juhl urged the joint committee to "stick with that drug on the OTC market place [and] examine the labeling to see if we can improve it."
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

PS083455

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel